JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i5.10756ArticleMultidimensional Strategies to Prevent and Control Risk Factors in Patients with Nonvalvular Atrial Fibrillation: Mechanistic Explorations and Advances in Clinical Practicehttps://artdesignp.com/journal/JCNR/9/5/10.26689/jcnr.v9i5.10756YangLi,XiangDongming,ZhongLiling,ZouYuling2025952025-06-05Background: Non-valvular atrial fibrillation (NVAF), the most prevalent cardiac arrhythmia globally, poses a dual challenge of thromboembolic and bleeding risks, with stroke being the most devastating complication. Despite advancements in anticoagulation and rhythm control, patient outcomes remain suboptimal. Aim: This review synthesizes current evidence on the pathophysiological mechanisms, multidimensional management strategies, and emerging innovations in NVAF to inform clinical practice and future research directions. Methods: A systematic literature search was conducted across nine databases (CNKI, Wanfang, SinoMed, VIP, PubMed, Web of Science, Cochrane Library, Embase, and MEDLINE) using combined Medical Subject Headings (MeSH) and free-text terms, including “atrial fibrillation,” “non-valvular atrial fibrillation,” “risk factors,” and “mechanism” (and their Chinese equivalents). Studies on NVAF pathogenesis, therapeutic interventions, and risk stratification tools were analyzed. Results: (1) Risk Factors and Pathophysiology: NVAF progression is driven by hemodynamic stress (e.g., hypertension), metabolic disorders (e.g., obesity, diabetes), chronic inflammation, and fibrosis. Biomarkers such as CRP and Galectin-3, along with TGF-β/Smad signaling, are central to atrial remodeling. (2) Anticoagulation Controversies: While NOACs reduce stroke risk compared to warfarin (HR = 0.79), challenges persist in extreme body weight populations and drug-drug interactions (e.g., with P-glycoprotein inhibitors). (3) Left Atrial Appendage Closure (LAAC): LAAC demonstrates non-inferiority to anticoagulation in stroke prevention (HR = 0.79) with reduced major bleeding (HR = 0.49), though device-related thrombosis (1.8–7%) remains a concern. (4) Precision Medicine: AI-driven models enhance stroke prediction (AUC = 0.71; sensitivity 92%), while genotype-guided warfarin dosing shortens INR stabilization by 40%. (5) Lifestyle Interventions: Combined Mediterranean diet and moderate exercise reduce AF burden (HR = 0.69) and reverse left atrial enlargement (LAVI reduced by 12%). (6) Multidisciplinary Care: Integrated “heart-brain team” approaches combining LAAC and PFO closure lower annual stroke recurrence from 8.2% to 2.1%, while comprehensive rehabilitation improves functional capacity (6MWD + 45 m) and quality of life (SF-36 + 12 points). Conclusion: NVAF management has evolved from isolated anticoagulation to a multidimensional paradigm integrating genomics, AI, and lifestyle modification. Future priorities include validating long-term outcomes of novel therapies, addressing evidence gaps in special populations, and implementing digitally enabled, cross-disciplinary care models to mitigate the global burden of NVAF-related complications.

Lippi G, Sanchis-Gomar F, Cervellin G, 2021, Global Epidemiology of Atrial Fibrillation: An Increasing Epidemic and Public Health Challenge. Int J Slmke, 16(2): 217–221.

Elliott A, Middeldorp M, Gelder I, et al., 2023, Epidemiology and Modifiable Risk Factors for Atrial Fibrillation. Nature Reviews Cardiology, 20(6): 404–417.

January C, Wann L, Calkins H, et al., 2019, 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation, 140(2): e125–e151.

Yang C, Hui Z, Zeng D, et al., 2021, A Community-Based Nurse-Led Medication Self-Management Intervention in the Improvement of Medication Adherence in Older Patients with Multimorbidity: Protocol for a Randomised Controlled Trial. BMC Geriatrics, 21: 1–15.

Hindricks G, Potpara T, Dagres N, et al., 2020, 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2020: ehaa612.

Sagris M, Vardas E, Theofilis P, et al., 2021, Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. International Journal of Molecular Sciences, 23(1): 6.

Zhuang T, Zhang S, 2024, Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024. Medical Journal of Peking Union Medical College Hospital, 15(4): 801–806.

Chen X, Liu H, 2024, Predictive Value of Essen Stroke Risk Score Combined with OX-LDL and UCH-1 for Short-Term Prognosis of Patients with First-Time Acute Ischemic Stroke in Non-Atrial Fibrillation Population. Journal of Xinjiang Medical University, 47(2): 254–258 + 263.

Huang C, Zhang S, Huang D, et al., 2018, Atrial Fibrillation: Current Understanding and Treatment Recommendations – 2018. Chinese Journal of Cardiac Pacing and Electrophysiology, 32(4): 315–368.

Staerk L, Sherer J, Ko D, et al., 2017, Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation Research, 120: 1501–1517.

Sagris M, Antonopoulos A, Theofilis P, et al., 2021, Risk Factors Profile of Young and Older Patients with Myocardial Infarction. Cardiovascular Research, 2021.

Diavati S, Sagris M, Terentes-Printzios D, et al., 2021, Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration. Current Pharmaceutical Design, 2021.

Hinderer S, Schenke-Layland K, 2019, Cardiac Fibrosis—A Short Review of Causes and Therapeutic Strategies. Advanced Drug Delivery Reviews, 146: 77–82.

Samman T, Sandesara P, Hayek S, et al., 2017, Association Between Oxidative Stress and Atrial Fibrillation. Heart Rhythm, 14: 1849–1855.

Yoshimoto A, Suematsu Y, Kurahashi K, et al., 2021, Early and Middle-Term Results and Anticoagulation Strategy After Left Atrial Appendage Exclusion Using an Epicardial Clip Device. Annals of Thoracic and Cardiovascular Surgery, 27(3): 185.

Deshmukh A, Iglesias M, Khanna R, et al., 2022, Healthcare Utilization and Costs Associated with a Diagnosis of Incident Atrial Fibrillation. Heart Rhythm, 3(5): 577–586.

Wei Y, Zhou G, Wu X, et al., 2023, Latest Incidence and Electrocardiographic Predictors of Atrial Fibrillation: A Prospective Study from China. Chinese Medical Journal (English), 136(3): 313–321.

Shi S, Tang Y, Zhao Q, et al., 2022, Prevalence and Risk of Atrial Fibrillation in China: A National Cross-Sectional Epidemiological Study. The Lancet Regional Health – Western Pacific, 23: 100439.

Ren Y, Li N, Lu J, et al., 2024, Study on the Evaluation of Stroke Risk in Patients with Non-Valvular Atrial Fibrillation by Echocardiography Combined with B-Type Natriuretic Peptide. Journal of Bengbu Medical College, 49(10): 1367–1370.

Zhao J, Chen M, Zhou X, et al., 2024, Diagnosis of Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation Using Dual-Energy CT. Journal of Sun Yat-sen University (Medical Sciences), 45(5): 745–754.

Xing Y, Zhang Y, Yao Z, et al., 2024, Construction and Validation of a Predictive Model for Cognitive Frailty in Elderly Patients with Atrial Fibrillation. Military Nursing, 41(7): 38–42.

Zhao Y, 2017, The Effect of Behavioral Intervention Based on the Transtheoretical Model on Cardiac Rehabilitation and Quality of Life in Patients after Percutaneous Coronary Intervention. International Medicine and Health Guidance News, 23(15): 2456–2460.

Ruff C, Giugliano R, Braunwald E, et al., 2014, Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet, 383(9921): 955–962.

Meid A, Wirbka L, Groll A, et al., 2022, Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants. Medical Decision Making, 42(5): 587–598.

Reddy V, Doshi S, Kar S, et al., 2017, 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. Journal of the American College of Cardiology, 70(24): 2964–2975.

Neumann F, Jagemann B, Makarova N, et al., 2022, Mediterranean Diet and Atrial Fibrillation: Lessons Learned from the AFHRI Case–Control Study. Nutrients, 14(17): 3615.

Freixa X, Arzamendi D, Tzikas A, et al., 2014, Cardiac Procedures to Prevent Stroke: Patent Foramen Ovale Closure/Left Atrial Appendage Occlusion. Canadian Journal of Cardiology, 30(1): 87–95.